Результаты исследовании INSIGHT в группе пациентов с сахарным диабетом и гипертонией

С целью получения дополнительной информации о возможностях терапии длительнодействующими препаратами дигидропиридинового ряда было проведено международное многоцентровое исследование INSIGHT (INTERVENTION AS A GOAL IN HYPERTENSION TREATMENT). Планировалось сравнить влияние приема нифедипина GITS и ко-амилозида на частоту развития различных неблагоприятных клинических исходов у больных с АГ и высоким риском развития сердечно-сосудистой заболеваемости и летальности. Нифедипин GITS (гастроинтестинальная терапевтическая система) относится к группе длительно действующих антагонистов кальциевых каналов дигидропиридинового ряда (ОСМО Адалат). Для сравнения использовался ко-амилозид ? комбинированный диуретический препарат, в состав которого входит амилорид - калийсберегающий диуретик, действующий на дистальную часть канальцев, и тиазидный диуретик гидрохлортиазид. Выбор диуретика как препарата сравнения обусловлен результатами ранее исследований, что данная группа препаратов значительно уменьшает частоту развития сердечно-сосудистых осложений у пациентов с А

INSIGHT, сахарный диабет, гипертония, нифедипин, ко-амилозид

1. G.Mancia, V. Brown, A.Castaigne, P.Leeuv, С.R.Palmer, T. Rosental, G.Wagener, L. M. Ruilope//Outcomes with nifedipin GITS or co-amilozide in hypertensive diabeics and non diabetics in Intervention as a goal in hypertension(INSIGHT) (Hypertension. 2003;41:431-436)

2. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting caldum-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372.

3. Curb J.D. Pressl S.L Cutler J. et al. SHEP Cooperative Reserch Group JAMA 1996. 276, 1886-1892

4. Kannel W.B. McGee D.L. Diabetes and cardiovascular risk factor: the Framingham Study. Circulation 1979; 59: 8-13

5. Hoffner S. Lehto S. Ronnemaa T. et al. Mortality from coronary heart disease in subject with type 2 diabetes and nondiabetic subjecct with and without myocardial infartion N.Engl. J.Med. 1 998;339:229-234

6. Padwal R. Straus SE, McAlister F A Evidence based management of hypertentension: cardiovascular risk factors and their effects on the decesion to treat hypertension: evidence based review. BMJ.2001;322:977-980

7. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001 ;37:1 053-1059

8. UK Prosctive Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular complcations in type2 diabetes:UKPDS 39 BMJ. 1998;317:713-720

9. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U,Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelmann J, Snapinn S, for the LIFE study group. Cardiovascular morbidity and mortality in patients wit+i diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010.

10. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.

11. Schrier RW, Estacio RO. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N Engl J Med. 2000;343:1969

12. Hansson L, Zanchetti A, Carruthers SG, Dahlof В, Elmfeldt D, Julius S,Menard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principol results of the Hypertension Optimal Treatment (HOT) randomised trial: HOT Study Group. Lancet. 1998;351: 1755-1762.

13. Lidholm LH, Hansson L, Ekbom T et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elredly diabetic patients: results from the SwedishTrial in Old Patients with Hypertension-2 STOP Hypertension Study Group. J. Hypertens. 2000; 18; 1671-1675.

14. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM Diabetes Care. 1 998; 21:597-603.

15. The Antihypertensive and Lipid-LowermgTreatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 2981-2997

16. Tuomilehto J, Rastenyte D, Berkenhager WH et al. Effect of calcium-channei blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Eng J Med. 1999,340:677-684

17. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nefropathy. N Engl J Med.2001; 345:851-860.

18. Parving HH, lehnert H, В rochner-Morten sen J, Gomis R et al. The effect of irbesartan on the development of diabetic nephropathy tn patients with type 2 diabetes. N Engl J Med. 2001; 345: 870-878.

19. Heart Outcomes Prevention Evaluation Study Investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes melitus: result of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.

20. Gong L. Zhang W, ZbuY, et al. Staghai Trial of Nifedipine in Eldederly (STONE) 1996; 14: 1237-1245

21. Perine С J, Handberg-Thurmond E, Marks P et al. Rationale and design of the International Verapamil SR| Trandolapril Study(INVEST) JACC1998; 32: 1228-1232

22. Zancheti I et al, Evropean Lacidipine Study on Aterosclerosis (ELSA) Fachzeitschrift Circulation 2002.10.1 161

23. Hansson L, Hender T, Lund-Johansen P et al. The Nordic Diltiazem (NORDIL) study. Lancet 2000; 356: 359-365

24. Kaplan NM. Hypertension trials: 1 990 to 2000. Curr Opin Nephrol Hypertens. 2001; 10; 501-505